CN106362221B - 一种具有抑菌促愈合功能的防粘连材料及其制备方法 - Google Patents
一种具有抑菌促愈合功能的防粘连材料及其制备方法 Download PDFInfo
- Publication number
- CN106362221B CN106362221B CN201610870752.2A CN201610870752A CN106362221B CN 106362221 B CN106362221 B CN 106362221B CN 201610870752 A CN201610870752 A CN 201610870752A CN 106362221 B CN106362221 B CN 106362221B
- Authority
- CN
- China
- Prior art keywords
- adhesion
- solution
- temperature
- sol
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000463 material Substances 0.000 title claims abstract description 86
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 40
- 230000035876 healing Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- -1 hydroxyl butyl Chemical group 0.000 claims abstract description 39
- 229920001661 Chitosan Polymers 0.000 claims abstract description 35
- 230000001737 promoting effect Effects 0.000 claims abstract description 32
- 229920002000 Xyloglucan Polymers 0.000 claims abstract description 29
- 230000002980 postoperative effect Effects 0.000 claims abstract description 15
- 230000007704 transition Effects 0.000 claims abstract description 15
- 230000029663 wound healing Effects 0.000 claims abstract description 15
- 150000004676 glycans Chemical class 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 230000003385 bacteriostatic effect Effects 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000012890 simulated body fluid Substances 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims 3
- 238000013329 compounding Methods 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 abstract description 10
- 229920001282 polysaccharide Polymers 0.000 abstract description 8
- 239000005017 polysaccharide Substances 0.000 abstract description 8
- 230000002269 spontaneous effect Effects 0.000 abstract description 5
- 230000009466 transformation Effects 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000002324 minimally invasive surgery Methods 0.000 abstract description 3
- 206010052428 Wound Diseases 0.000 description 21
- 208000027418 Wounds and injury Diseases 0.000 description 21
- 239000000499 gel Substances 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 9
- 241000252983 Caecum Species 0.000 description 8
- 210000004534 cecum Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000518 rheometry Methods 0.000 description 8
- 206010060932 Postoperative adhesion Diseases 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000008279 sol Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 206010000050 Abdominal adhesions Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 238000004146 energy storage Methods 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 238000002682 general surgery Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/145—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明提供一种具有抑菌促愈合功能的防粘连材料及其制备方法;防粘连材料具有温度响应性,随着温度的升高能够自发的发生从溶胶到凝胶的转变,溶胶‑凝胶转变温度在5~37℃。采用的原料是具有良好生物相容性和生物可降解性的天然基多糖木葡聚糖和羟丁基壳聚糖,通过两种多糖溶液的简单共混制备具有可控溶胶‑凝胶转变温度的可注射温敏凝胶作为防粘连材料。本发明制备的防粘连材料可用于预防粘连松解术后再粘连的发生,同时具有抑菌和促进创面愈合的功能。提供的防粘连材料制备方法简单,参数可控,在用于预防粘连松解术后再粘连时提高了术后操作的便利性,并能结合微创手术,具有很好的临床应用前景。
Description
技术领域
本发明涉及一种具有抑菌促愈合功能的防粘连材料及其制备方法,属于生物医用材料领域。
背景技术
术后粘连是外科手术领域普遍存在的问题,也是临床中长期未能解决的医学难题之一。手术后的粘连可能会引起严重的并发症,如肠梗阻、慢性疼痛、女性的异位妊娠、不孕不育等,严重的甚至会导致死亡。为了减弱或消除术后粘连给患者所带来的影响,临床上对于既已形成的粘连大都采用粘连松解手术进行分离。粘连松解术虽然解除了已经形成的粘连,但在对粘连组织分离的同时又会造成新的创伤,因而可能会导致粘连松解部位再次粘连的发生。临床研究显示,粘连松解术后发生再粘连的发生率高达50%,因此对于粘连松解术后再粘连的预防研究具有非常重要的临床意义。
现有的防粘连材料,无论是固态的防粘连膜还是溶液或凝胶类的液态防粘连材料,它们针对的是普通手术创伤所造成的粘连,而对于粘连松解术后再粘连的预防研究非常少,相关的专利也未见有报道。相对于常规外科手术创伤所导致的粘连,粘连松解手术对粘连组织所造成的创伤更为严重,而且再粘连的形成机制也更加复杂,所以,对于能够有效预防普通手术后粘连的物理屏障材料,其在用于预防粘连松解术后再粘连的发生时,往往不能显示出良好的防粘连效果。
壳聚糖是一种具有良好生物相容性和可降解性的天然多糖。大量研究表明,壳聚糖不仅能够抑制成纤维细胞的增生和降低胶原纤维的产生,而且能够促进内皮细胞生长,从而促进伤口愈合。因此,如果将壳聚糖作为术后防粘连材料,则能够有效的促进术后创面的愈合并减少瘢痕的形成。但是由于壳聚糖本身难溶于水,所以很大程度上限制了它的应用。为了改善壳聚糖的水溶性,研究者通过不同的化学修饰方法对壳聚糖进行改性,分别制备了水溶性的羧甲基化、酰基化、烷基化以及季铵化壳聚糖等壳聚糖衍生物,极大地拓展了它在各个领域的应用。尽管大多数的壳聚糖衍生物都具有很好的水溶性,但是往往都不具有温度响应性,无法作为可注射水凝胶用于术后防粘连领域。因此,如果能够在保持壳聚糖良好生物相容性和可降解性的同时改善其水溶性并赋予其优异的温敏性能,则可极大地拓展其在生物医学领域的应用。
感染是导致术后粘连的诸多因素之一,之前的研究大都忽略了细菌感染对粘连形成的影响,尤其是对于腹腔粘连,由于创面暴露于富含大量腹腔液的潮湿环境中,极大地提高了细菌感染的几率,从而增加了术后粘连的发生率。例如大肠杆菌感染所导致的渗出液中含有大量的纤维蛋白及白细胞,因而会导致密性粘连的形成。壳聚糖是一种具有广谱抗菌性能的天然多糖,对于许多种细菌均呈现出良好的抗菌活性。如果能在赋予壳聚糖优异温敏性的同时保持其良好的抑菌活性,则将其用作术后防粘连材料时就能够同时发挥物理屏障和抗感染的协同作用,再结合其促进创面愈合的性能,从而可以极大的提高其预防术后粘连和促进创面愈合的效果。
申请号为200910052695.7的中国专利公开了温敏性几丁糖制剂的制备方法及其在术后组织粘连方面的应用,虽然这种温敏性的几丁糖制剂在以大鼠为实验动物的普通腹腔手术后显示了良好的防粘连效果,但是根据我们的研究结果,其在用于创伤更为严重的粘连松解手术后并不能有效地预防再粘连的发生。因此,开发新型的能够有效预防粘连松解术后再粘连发生的防粘连材料是术后防粘连领域的技术人员所面临的难题。
发明内容
本发明的目的在于提供一种具有抑菌促愈合功能的防粘连材料,以解决现有技术中术后防粘连材料不能有效预防粘连松解术后再粘连发生的问题。本发明同时提供了一种具有抑菌促愈合功能的防粘连材料的制备方法,采用的原料是具有良好生物相容性和生物可降解性的天然基多糖木葡聚糖和羟丁基壳聚糖,通过两种本身具有温敏性的多糖溶液的简单共混制备具有可控溶胶-凝胶转变温度的可注射温敏凝胶作为防粘连材料,由于,本发明所制备的防粘连材料结合了羟丁基壳聚糖溶液的抑菌、促进创面愈合能力和木葡聚糖溶液的预防术后粘连性能,因可用于预防更为复杂的粘连松解术后再粘连的发生,并同时具有抑菌和促进创面愈合的功能。
本发明是通过以下的技术方案加以实现的:
一种具有抑菌促愈合功能的防粘连材料,所述防粘连材料是由木葡聚糖溶液和羟丁基壳聚溶液复合而成。
所述防粘连材料具有温度响应性,随着温度的升高能够自发的发生从溶胶到凝胶的转变,溶胶-凝胶转变温度在5~37℃。
具体地,所述术后防粘连材料中木葡聚糖溶液和羟丁基壳聚溶液所使用的溶剂为纯水、生理盐水、缓冲溶液、细胞培养基、模拟体液、动物或人体体液其中的一种或一种以上的混合溶液。
本发明还公开了上述具有抑菌促愈合功能的防粘连材料的制备方法,包括以下步骤:
(1)在4℃条件下将分子量为5万~500万,侧链半乳糖脱除率为35~95%的木葡聚糖溶于溶剂中,得到质量分数为0.1~20%的木葡聚糖溶液;
(2)在4℃条件下将分子量为5万~500万,羟丁基取代度为0.5~2.0的羟丁基壳聚糖溶于溶剂中,得到质量分数为0.1~20%的羟丁基壳聚糖溶液;
(3)在4℃条件下将步骤(1)所得到的木葡聚糖溶液和步骤(2)所得到的羟丁基壳聚溶液按体积比0.5~9.5:9.5~0.5进行复合,即可得到具有抑菌促愈合功能的防粘连材料。
具体地,步骤(1)所得到的木葡聚糖溶液具有温度响应性,随着温度的升高能够自发的发生从溶胶到凝胶的转变,溶胶-凝胶转变温度为5~37℃。
具体地,步骤(2)所得到的羟丁基壳聚糖溶液具有温度响应性,随着温度的升高能够自发的发生从溶胶到凝胶的转变,溶胶-凝胶转变温度为5~37℃。
本发明与现有技术相比,其优点在于:(1)本发明通过两种具有不同性能的多糖溶液的简单共混得到了兼具两种多糖优异性能的防粘连材料,解决了现有技术中术后防粘连材料不能有效预防粘连松解术后再粘连发生的问题(图8)。(2)本发明所制备的防粘连材料以多糖基材料木葡聚糖和羟丁基壳聚糖为原料,使用的溶剂为水等绿色溶剂,制备过程中完全避免了有机试剂的使用,具有良好的生物相容性和生物可降解性。(3)本发明所制备的防粘连材料能够在生理温度下快速地自发形成水凝胶(图1,2,3,4),避免了化学交联剂的使用和化学反应的发生,具有良好的生物安全性。(4)本发明所制备的术后防粘连材料含有羟丁基壳聚糖,在预防术后粘连的同时能够起到抑菌(图6)和促进创面愈合的效果(图7)。(5)本发明所提供的防粘连材料制备方法简单,参数可控,使用方便,并能结合微创手术,为粘连松解术后再粘连的预防提供了新的选择,具有很好的临床应用前景。
本发明公开的一种具有抑菌促愈合功能的防粘连材料及其制备方法,防粘连材料由改性木葡聚糖溶液和羟丁基壳聚溶液复合而成,能够解决现有技术中防粘连材料不能有效预防粘连松解术后再粘连发生的问题。本发明提供了一种具有抑菌促愈合功能的防粘连材料的制备方法,采用的原料是具有良好生物相容性和生物可降解性的天然基多糖木葡聚糖和羟丁基壳聚糖,通过两种多糖溶液的简单共混制备具有可控溶胶-凝胶转变温度的可注射温敏凝胶作为防粘连材料。本发明所制备的防粘连材料可用于预防粘连松解术后再粘连的发生,同时具有抑菌和促进创面愈合的功能。提供的防粘连材料制备方法简单,参数可控,在用于预防粘连松解术后再粘连时提高了术后操作的便利性,并能结合微创手术,具有很好的临床应用前景。
附图说明
图1为本发明实施例1制备的具有抑菌促愈合功能的防粘连材料的储能模量(G')和损耗模量(G”)的温度扫描流变学结果。
图2为本发明实施例1制备的具有抑菌促愈合功能的防粘连材料在37℃下储能模量(G')和损耗模量(G”)的时间扫描流变学结果。
图3为本发明实施例2制备的具有抑菌促愈合功能的防粘连材料的储能模量(G')和损耗模量(G”)的温度扫描流变学结果。
图4为本发明实施例2制备的具有抑菌促愈合功能的防粘连材料在37℃下储能模量(G')和损耗模量(G”)的时间扫描流变学结果。
图5为本发明实施例3制备的具有抑菌促愈合功能的防粘连材料在不同温度下的表观状态。
图6为本发明实施例3制备的具有抑菌促愈合功能的防粘连材料对于大肠杆菌、绿脓杆菌和金黄色葡萄球菌的抑菌效果。
图7为本发明实施例1和3制备的具有抑菌促愈合功能的防粘连材料在用于SD大鼠皮肤创面模型术后14天的促进创面愈合效果。A:大鼠皮肤创面的建立;B:对照组;C,实施例1术后防粘连材料的促进创面愈合情况;D:实施例3术后防粘连材料的促进创面愈合情况。
图8为本发明实施例1制备的具有抑菌促愈合功能的防粘连材料在SD大鼠腹壁-盲肠粘连松解术后二次损伤粘连模型中术后7天的防粘连效果照片。A:使用生理盐水的对照组发生粘连;B:使用具有抑菌促愈合功能的防粘连材料的动物没有发生粘连并且创面愈合良好。
具体实施方式
实施例1
(1)在4℃条件下将分子量为100万,侧链半乳糖脱除率为41%的木葡聚糖溶于水中,得到质量分数为4%的木葡聚糖溶液;
(2)在4℃条件下将分子量为40万,羟丁基取代度为1.67的羟丁基壳聚糖溶于水中,得到质量分数为5%的羟丁基壳聚糖溶液;
(3)在4℃条件下将步骤(1)所得到的木葡聚糖溶液和步骤(2)所得到的羟丁基壳聚溶液按体积比5:5进行复合,即可得到具有抑菌促愈合功能的防粘连材料。
对本实施例得到的具有抑菌促愈合功能的防粘连材料,温度扫描的流变学结果显示本实施例得到的防粘连材料具有温度响应性,能够随着温度的升高自发的发生从溶胶到凝胶的转变,溶胶-凝胶转变温度为26℃;时间扫描的流变学结果显示本实施例得到的防粘连材料在37℃下20秒即可发生凝胶化。
实施例2
本实例与实例1的步骤基本相同,不同之处在于:将实例1中步骤(3)中木葡聚糖溶液和羟丁基壳聚溶液的体积比由5:5改为3:7,得到具有抑菌促愈合功能的防粘连材料。对本实施例得到的具有抑菌促愈合功能的防粘连材料,温度扫描的流变学结果显示本实施例得到的防粘连材料具有温度响应性,能够随着温度的升高自发的发生从溶胶到凝胶的转变,溶胶-凝胶转变温度为28℃;时间扫描的流变学结果显示本实施例得到的防粘连材料在37℃下25秒即可发生凝胶化。
实施例3
本实例与实例1的步骤基本相同,不同之处在于:将实例1中步骤(3)中木葡聚糖溶液和羟丁基壳聚溶液的体积比由5:5改为0.5:9.5,得到具有抑菌促愈合功能的防粘连材料。对本实施例得到的具有抑菌促愈合功能的防粘连材料,小瓶倒置法结果表明本实施例得到的防粘连材料具有可逆的“低温溶胶,高温凝胶”转变行为;抑菌圈实验结果显示,浸渍过本实施例制备的防粘连材料的滤纸片周围均出现了明显的抑菌圈,说明本实施例制备的防粘连材料对于大肠杆菌、绿脓杆菌和金黄色葡萄球菌具有抑菌效果。
实施例4
(1)在4℃条件下将分子量为500万,侧链半乳糖脱除率为35%的木葡聚糖溶于水中,得到质量分数为1%的木葡聚糖溶液;
(2)在4℃条件下将分子量为5万,羟丁基取代度为2.0的羟丁基壳聚糖溶于水中,得到质量分数为20%的羟丁基壳聚糖溶液;
(3)在4℃条件下将步骤(1)所得到的木葡聚糖溶液和步骤(2)所得到的羟丁基壳聚溶液按体积比5:5进行复合,即可得到具有抑菌促愈合功能的防粘连材料。实施例5
(1)在4℃条件下将分子量为10万,侧链半乳糖脱除率为90%的木葡聚糖溶于水中,得到质量分数为10%的木葡聚糖溶液;
(2)在4℃条件下将分子量为500万,羟丁基取代度为1.0的羟丁基壳聚糖溶于水中,得到质量分数为0.5%的羟丁基壳聚糖溶液;
(3)在4℃条件下将步骤(1)所得到的木葡聚糖溶液和步骤(2)所得到的羟丁基壳聚溶液按体积比7:3进行复合,即可得到具有抑菌促愈合功能的防粘连材料。实施例6
(1)在4℃条件下将分子量为5万,侧链半乳糖脱除率为50%的木葡聚糖溶于水中,得到质量分数为20%的木葡聚糖溶液;
(2)在4℃条件下将分子量为100万,羟丁基取代度为0.6的羟丁基壳聚糖溶于水中,得到质量分数为15%的羟丁基壳聚糖溶液;
(3)在4℃条件下将步骤(1)所得到的木葡聚糖溶液和步骤(2)所得到的羟丁基壳聚溶液按体积比9:1进行复合,即可得到具有抑菌促愈合功能的防粘连材料。实施例7
本实施例是将本发明制备的具有抑菌促愈合功能的防粘连材料在SD大鼠的皮肤创面模型中进行应用以考察其促进创面愈合效果。
具体方法是将实验动物SD大鼠麻醉、消毒后在脊柱两侧间距2cm的肩胛区分别切取直径2cm的创面,之后将1mL实施例1和3制备的防粘连材料注射至创面,然后以消毒敷料覆盖创面;对照组创面仅以无菌消毒敷料覆盖。实验组创面每两天注射一次防粘连材料,并用消毒敷料覆盖,同时对对照组创面更换消毒敷料。术后14天结果显示,相对于对照组,使用实施例1和3制备的防粘连材料的动物,其创面具有更快的愈合速度,创面愈合情况良好,并且无炎症反应出现。
实施例8
本实施例是将本发明制备的具有抑菌促愈合功能的防粘连材料在SD大鼠腹壁-盲肠粘连松解术后二次损伤粘连模型中进行应用以考察其对粘连松解术后再粘连的预防效果。
具体方法是将实验动物SD大鼠麻醉、消毒后在腹白线位置开腹,使用眼科剪在腹壁剥离1×2cm2大小的浅层肌,形成出血表面;然后在与腹壁创面相对应的盲肠表面使用手术刷磨擦直到盲肠浆膜层被破坏至有明显的点状出血;之后用3-0缝合线将盲肠的肠系膜缝合固定于腹壁创面的右上角处,以保证腹壁和盲肠的创伤面相互之间能够充分接触而形成粘连。术后一周,对动物进行二次开腹手术,使用钝器或锐器对形成的粘连进行松解,用手术刷反复摩擦分离后的腹壁创面直至再次形成出血表面;然后用手术刷在分离后的盲肠创面部位轻轻磨擦直到肠粘膜再次被破坏至有明显的渗血;最后将1mL实施例1制备的具有抑菌促愈合功能的防粘连材料注射至粘连松解术后二次损伤的腹壁和盲肠创面,待凝胶完全固化后关腹。
术后7天开腹,使用实施例1制备的温敏可注射术后防粘连材料的动物没有发生任何形式的粘连,腹壁创面已经完全愈合,愈合后的创面表面光洁平整,几乎看不到疤痕存在,受损的盲肠也愈合良好;而使用生理盐水的对照组中受损的盲肠和腹壁之间发生了致密的粘连。
上述实施例是本发明较佳的实施方式,但本发明不限定于上述的实施例。在不脱离本发明技术方案的精神和范围的基础上对本发明的技术方案进行的修改或者等同替换,均应包含在本发明的保护范围内。
Claims (5)
1.一种具有抑菌促愈合功能的防粘连材料,其特征在于,所述防粘连材料是由木葡聚糖溶液和羟丁基壳聚糖溶液复合而成;所述防粘连材料具有温度响应性,随着温度的升高能够自发的发生从溶胶到凝胶的转变,溶胶-凝胶转变温度为5~37℃;制备方法包括以下步骤:
(1)在4℃条件下将分子量为5万~500万,侧链半乳糖脱除率为35~95%的木葡聚糖溶于溶剂中,得到质量分数为0.1~20%的木葡聚糖溶液;
(2)在4℃条件下将分子量为5万~500万,羟丁基取代度为0.5~2.0的羟丁基壳聚糖溶于溶剂中,得到质量分数为0.1~20%的羟丁基壳聚糖溶液;
(3)在4℃条件下将步骤(1)所得到的木葡聚糖溶液和步骤(2)所得到的羟丁基壳聚糖溶液按体积比0.5~9.5:9.5~0.5进行复合,得到具有抑菌促愈合功能的防粘连材料。
2.根据权利要求1所述的防粘连材料,其特征在于,步骤(1)所得到的木葡聚糖溶液具有温度响应性,随着温度的升高能够自发的发生从溶胶到凝胶的转变,溶胶-凝胶转变温度为5~37℃。
3.根据权利要求1所述的防粘连材料,其特征在于,步骤(2)所得到的羟丁基壳聚糖溶液具有温度响应性,随着温度的升高能够自发的发生从溶胶到凝胶的转变,溶胶-凝胶转变温度为5~37℃。
4.根据权利要求1所述的材料,其特征在于,所述术后防粘连材料中木葡聚糖溶液和羟丁基壳聚糖溶液所使用的溶剂为纯水、生理盐水、缓冲溶液、细胞培养基、模拟体液、动物或人体体液其中的一种或一种以上的混合溶液。
5.根据权利要求1所述的防粘连材料,其特征在于,所述防粘连材料用于预防粘连松解术后再粘连的发生,同时具有抑菌和促进创面愈合的功能。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610870752.2A CN106362221B (zh) | 2016-09-30 | 2016-09-30 | 一种具有抑菌促愈合功能的防粘连材料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610870752.2A CN106362221B (zh) | 2016-09-30 | 2016-09-30 | 一种具有抑菌促愈合功能的防粘连材料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106362221A CN106362221A (zh) | 2017-02-01 |
CN106362221B true CN106362221B (zh) | 2019-06-21 |
Family
ID=57897816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610870752.2A Active CN106362221B (zh) | 2016-09-30 | 2016-09-30 | 一种具有抑菌促愈合功能的防粘连材料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106362221B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109876181A (zh) * | 2019-04-11 | 2019-06-14 | 陕西仁浩医疗器械有限公司 | 一种抗炎镇痛、促进伤口愈合、提高免疫力的医用凝胶 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996002258A1 (en) * | 1994-07-19 | 1996-02-01 | Astra Aktiebolag | Anti-adhesion agent |
CN101820885A (zh) * | 2007-10-03 | 2010-09-01 | Cpn有限公司 | 包含壳聚糖-葡聚糖的用于伤口愈合并防止绷带粘连伤口的制剂 |
-
2016
- 2016-09-30 CN CN201610870752.2A patent/CN106362221B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996002258A1 (en) * | 1994-07-19 | 1996-02-01 | Astra Aktiebolag | Anti-adhesion agent |
CN101820885A (zh) * | 2007-10-03 | 2010-09-01 | Cpn有限公司 | 包含壳聚糖-葡聚糖的用于伤口愈合并防止绷带粘连伤口的制剂 |
Non-Patent Citations (2)
Title |
---|
可注射温敏木葡聚糖水凝胶在预防术后粘连中的应用;张二帅等;《2015年全国高分子学术论文报告会》;20151021;第335页全文 |
羟丁基壳聚糖预防大鼠腹腔粘连的实验研究;刘双利等;《中国修复重建外科杂志》;20090630;第23卷(第6期);摘要、第718页右栏第1段至第721页右栏第2段 |
Also Published As
Publication number | Publication date |
---|---|
CN106362221A (zh) | 2017-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210322626A1 (en) | Dissolvable nasal sinus sponge | |
US11787922B2 (en) | Hydrophobically modified chitosan compositions | |
Yang et al. | H-bonding supramolecular hydrogels with promising mechanical strength and shape memory properties for postoperative antiadhesion application | |
US9533005B2 (en) | Modified starch material of biocompatible hemostasis | |
JP5883895B2 (ja) | 生物相容性の止血、癒着防止、癒合促進、外科密封可能な変性澱粉材料 | |
CN104981259B (zh) | 包含防粘连的水凝胶膜的试剂盒 | |
ES2787423T3 (es) | Empaque y stent hemostático biorreabsorbible flexible | |
CN101053669B (zh) | 一种水溶性壳聚糖基止血愈创海绵及其制备方法和应用 | |
JP2017522162A (ja) | 高分子フォーム組成物、それを用いた高分子フォームの製造方法、及びパッキング用高分子フォーム | |
JP2007526094A (ja) | 生物医学的閉塞デバイス、涙点プラグ、及びそれらの使用方法 | |
US9198997B2 (en) | Rehydratable thiolated polysaccharide particles and sponge | |
CN101564557B (zh) | 用于一次性宫颈扩张器的抗菌自膨胀材料的制备方法 | |
Zhou et al. | Preparation and application of hemostatic hydrogels | |
CN107088236A (zh) | 一种增强型抗菌止血生物海绵的制备方法 | |
CN106362221B (zh) | 一种具有抑菌促愈合功能的防粘连材料及其制备方法 | |
CN114917400B (zh) | 一种聚赖氨酸抗菌组织粘合剂及应用 | |
JP2003153999A (ja) | 医用材料 | |
RU2509784C2 (ru) | Способ получения пористых, пленочных материалов на основе карбоксиметилцеллюлозы | |
KR20020011955A (ko) | 유착방지제 | |
CN116099059B (zh) | 一种可注射抗菌堵瘘水凝胶及其制备方法 | |
JP2008543922A (ja) | 生体吸収性ヒドロゲル | |
CN106362222A (zh) | 一种温敏可注射术后防粘连材料及其制备方法 | |
CN105363075A (zh) | 一种用于止血和防粘连的可吸收医用材料及其制备方法 | |
JP2003019194A (ja) | ヒアルロン酸とカルボキシメチルセルロースからなる共架橋ゲル組成物 | |
CN118892571A (zh) | 一种多功效的可降解组织粘合贴片及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220124 Address after: No. 333, Songling Road, Laoshan District, Qingdao City, Shandong Province 266100 Patentee after: QINGDAO CHENLAND MARINE BIOTECHNOLOGY Co.,Ltd. Address before: 300072 Tianjin University, No.92 Weijin Road, Nankai District, Tianjin Patentee before: Tianjin University |
|
TR01 | Transfer of patent right |